KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Framingham, MA, US. The stock last traded at $27.00, up 0.00% on the session, giving a market capitalisation of $1.44B. On trailing twelve-month figures it carries a trailing P/E of -8.36, a net margin of -119.4%. Its beta of -0.29 implies it has historically moved less than the broad market.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
KalVista Pharmaceuticals, Inc. is most often compared with the following Healthcare names: